All In Biotech

Drug Trial Radar · NCT05192941

Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

Efficacy, Safety, Tolerability and Quality of Life of Ongoing Individually Optimized Lipid-lowering Therapy With or Without Inclisiran (KJX839) - a Randomized, Placebo-controlled, Double-blind Multicenter Phase IV Study in Participants With Hypercholesterolemia

Last checked: Nov 20, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,770 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,770

Actual

Start

Apr 8, 2022

Primary completion

Jun 11, 2024

Study completion Mar 19, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia

Conditions

  • Hypercholesterolemia

Interventions

  • Inclisiran SodiumDrug

    Subcutaneously injected on Day 1, Day 90, and Day 270

  • PlaceboDrug

    Placebo to inclisiran 300 mg subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Achieving Individual LDL-C Target (<55 mg/dL or <70 mg/dL)Time frame: Day 90

Locations

136 sites in 8 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Burgas, Bulgaria

  • Novartis Investigative Site

    Gabrovo, Bulgaria

  • Novartis Investigative Site

    Pleven, Bulgaria

  • Novartis Investigative Site

    Plovdiv, Bulgaria

  • Novartis Investigative Site

    Rousse, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Stara Zagora, Bulgaria

  • Novartis Investigative Site

    Varna, Bulgaria

  • Novartis Investigative Site

    Veliko Tarnovo, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria, Bulgaria

  • Novartis Investigative Site

    Burgas, Burgas, Bulgaria

  • Novartis Investigative Site

    Hlučín, Czechia

  • Novartis Investigative Site

    Hodonín, Czechia

  • Novartis Investigative Site

    Mělník, Czechia

  • Novartis Investigative Site

    Olomouc, Czechia

  • Novartis Investigative Site

    Olomouc, Czechia

  • Novartis Investigative Site

    Pardubice, Czechia

  • Novartis Investigative Site

    Slaný, Czechia

  • Novartis Investigative Site

    Trutnov, Czechia

  • Novartis Investigative Site

    Chlumec nad Cidlinou, Chlumec Nad Cidlinou, Czechia

  • Novartis Investigative Site

    Přerov, Olomouc Region, Czechia

  • Novartis Investigative Site

    Pärnu, Estonia

  • Novartis Investigative Site

    Tallinn, Estonia

  • Novartis Investigative Site

    Tallinn, Estonia

  • Novartis Investigative Site

    Tartu, Estonia

  • Novartis Investigative Site

    Amiens, France

  • Novartis Investigative Site

    Chambéry, France

  • Novartis Investigative Site

    Le Chesnay, France

  • Novartis Investigative Site

    Le Kremlin-Bicêtre, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Nantes, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Valenciennes, France

  • Novartis Investigative Site

    Bad Homburg, Germany

  • Novartis Investigative Site

    Bad Krozingen, Germany

  • Novartis Investigative Site

    Bad Oeynhausen, Germany

  • Novartis Investigative Site

    Bamberg, Germany

Showing 40 of 136 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.